title: Application of radiofrequency ablation for the treatment of metastatic liver cancers.
abstract: OBJECTIVE
  The aim of this study is to elucidate the effectiveness of radiofrequency ablation (RFA) for the treatment of metastatic liver cancers.
  
  
  METHODS
  From 74 patients with metastatic liver cancers treated by RFA, 40 patients including 23 colon cancer who had received curative resection of the primary tumor were analyzed.
  
  
  RESULTS
  Recurrence of the tumor was observed in 29 (72.5%) patients. The most prevalent site of recurrence was the liver in both colon cancer (10/15, 66.7%) and non-colon cancer patients (12/14, 85.7%). Among the recurrence in the liver, the rate of intrahepatic distant recurrence (recurrence outside of the RFA-treated segment) was high in both colon cancer (55.6%) and non-colon cancer patients (69.0%). Local recurrence (recurrence at the RFA-treated segment) rate was low (32.6% and 32.9%, respectively) and none of single tumor less than 2 cm in diameter showed local recurrence. The intrahepatic recurrence was single in 67.6% of the patients and 59.1% of the patients were re-treated by RFA.
  
  
  CONCLUSIONS
  RFA is a less-invasive method for the treatment of metastatic liver tumors and can be performed repetitively. Although the rate of intra-hepatic distant recurrence and extra-hepatic recurrence was high, good local control can be achieved by RFA.
authors.affiliation: Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences 2-5-1 Shikata-cho, Okayama-city, Okayama, 700-8558 Japan. nouso@cc.okayama-u.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nouso
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakamura
authors.forename: Shuji
authors.initials: S
authors.lastname: Uematsu
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Shiraga
authors.forename: Shouta
authors.initials: S
authors.lastname: Iwadou
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Araki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Hironori
authors.initials: H
authors.lastname: Tanaka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Toshikuni
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kaneyoshi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ikeda
authors.forename: Shinichi
authors.initials: S
authors.lastname: Fujioka
authors.forename: Toshiya
authors.initials: T
authors.lastname: Osawa
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Hidenori
authors.initials: H
authors.lastname: Shiraha
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D017115:Catheter Ablation; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D018579:Patient Selection; D015996:Survival Rate; D016896:Treatment Outcome